TY - ADVS
T1 - Adding Oral Alisertib to Weekly Paclitaxel for Metastatic Breast Cancer
AU - Cutter, Noelle L
PY - 2021/5/26
Y1 - 2021/5/26
N2 - A randomized phase II trial investigated the effect of adding the Aurora kinase A inhibitor alisertib to a reduced dose of weekly paclitaxel in the treatment of patients with estrogen receptor–positive, ERBB2-negative, or triple-negative metastatic breast cancer. According to Joyce O’Shaughnessy, MD, and researchers from Baylor University Medical Center, Dallas, the combination treatment significantly improved progression-free survival compared with paclitaxel alone. Their findings were published in JAMA Network Open.
AB - A randomized phase II trial investigated the effect of adding the Aurora kinase A inhibitor alisertib to a reduced dose of weekly paclitaxel in the treatment of patients with estrogen receptor–positive, ERBB2-negative, or triple-negative metastatic breast cancer. According to Joyce O’Shaughnessy, MD, and researchers from Baylor University Medical Center, Dallas, the combination treatment significantly improved progression-free survival compared with paclitaxel alone. Their findings were published in JAMA Network Open.
UR - https://jnccn360.org/breast/news/adding-oral-alisertib-to-weekly-paclitaxel-for-metastatic-breast-cancer/
M3 - Web publication/site
ER -